Login to Your Account

Competition doesn't always translate into cheaper drug prices

By Mari Serebrov
Regulatory Editor

Wednesday, January 18, 2017

Countering the congressional clamor for more competition and negotiations to reduce prescription drug prices in the U.S., the biopharma industry is providing some context that shows competition among branded drugs and tough negotiations often translate into bigger rebates, not cheaper prices for patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription